Cargando…

Cytomegalovirus infection among patients with cancer receiving immune checkpoint inhibitors

BACKGROUND: Immune checkpoint inhibitors (ICIs), used for the treatment of solid and hematologic malignancies, come with the risk of immune-related adverse events (irAEs). Opportunistic infections (e.g., cytomegalovirus [CMV]) mimic irAE symptoms and are understudied in this population. We aimed to...

Descripción completa

Detalles Bibliográficos
Autores principales:	Panneerselvam, Kavea, Szafron, David, Amin, Rajan N., Wei, Dongguang, Tan, Dongfeng, Altan, Mehmet, Okhuysen, Pablo C., Shatila, Malek, Raju, Gottumukkala Subba, Thomas, Anusha S., Wang, Yinghong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hellenic Society of Gastroenterology 2022
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9399572/ https://www.ncbi.nlm.nih.gov/pubmed/36061160 http://dx.doi.org/10.20524/aog.2022.0735

Ejemplares similares

Clostridioides difficile infection in cancer patients receiving immune checkpoint inhibitors
por: Vasavada, Shaleen, et al.
Publicado: (2022)

Severe Inflammatory Colitis Related to Encorafenib and Binimetinib following Immune Checkpoint Inhibitor Therapy
por: Issac, Aaron G., et al.
Publicado: (2022)

Diarrhea and colitis related to immune checkpoint inhibitor and BRAF/MEK inhibitor therapy
por: Kuang, Andrew G., et al.
Publicado: (2023)

Correction to: Impact of antibiotic therapy on the development and response to treatment of immune checkpoint inhibitor-mediated diarrhea and colitis
por: Abu-Sbeih, Hamzah, et al.
Publicado: (2019)

Impact of antibiotic therapy on the development and response to treatment of immune checkpoint inhibitor-mediated diarrhea and colitis
por: Abu-Sbeih, Hamzah, et al.
Publicado: (2019)

Importance of endoscopic and histological evaluation in the management of immune checkpoint inhibitor-induced colitis
por: Abu-Sbeih, Hamzah, et al.
Publicado: (2018)

Colon Adenoma After Diagnosis of Immune Checkpoint Inhibitor-mediated Colitis
por: Machado, Antonio Pizuorno, et al.
Publicado: (2023)

Clinical Features and Management of Acute and Chronic Radiation-Induced Colitis and Proctopathy
por: Abu-Sbeih, Hamzah, et al.
Publicado: (2023)

Esophageal Perforation Successfully Treated With EVT
por: Panneerselvam, Kavea, et al.
Publicado: (2022)

The Safety of Immunosuppressants Used in the Treatment of Immune-Related Adverse Events due to Immune Checkpoint Inhibitors: a Systematic Review
por: Machado, Antonio Pizuorno, et al.
Publicado: (2023)

Current and Future Perspectives in the Diagnosis and Management of Helicobacter pylori Infection
por: Shatila, Malek, et al.
Publicado: (2022)

Clinical characteristics of colitis induced by taxane-based chemotherapy
por: Chen, Ellie, et al.
Publicado: (2020)

Clinical Characteristics and Outcomes of Patients with Positive Celiac Serology and Cancer Therapy Exposure
por: Dutra, Barbara Erthal Smeral, et al.
Publicado: (2022)

Immune-checkpoint inhibitor-induced diarrhea and colitis in patients with advanced malignancies: retrospective review at MD Anderson
por: Wang, Yinghong, et al.
Publicado: (2018)

Obesity Measured via Body Mass Index May Be Associated with Increased Incidence but Not Worse Outcomes of Immune-Mediated Diarrhea and Colitis
por: Kono, Miho, et al.
Publicado: (2023)

656. Cryptosporidiosis in Immunocompromised Patients with Cancer Receiving Chemotherapy, CAR-T Cell Therapy and Hematopoietic Stem Cell Transplantation: A Retrospective Analysis
por: Mann, Inderjit, et al.
Publicado: (2023)

Immune checkpoint inhibitor-related gastrointestinal toxicity in patients with malignancy involving the luminal gastrointestinal tract and its impact on cancer outcomes
por: Yu, Kevin, et al.
Publicado: (2022)

Clinical characteristics and outcomes of immune checkpoint inhibitor-induced pancreatic injury
por: Abu-Sbeih, Hamzah, et al.
Publicado: (2019)

Safety and efficacy of fecal microbiota transplantation to treat and prevent recurrent Clostridioides difficile in cancer patients
por: Ali, Hiba, et al.
Publicado: (2021)

M412 A BALANCING ACT: TREATMENT OF COVID-19 AND CYTOMEGALOVIRUS IN A PATIENT WITH PRIMARY IMMUNODEFICIENCY
por: Szafron, V., et al.
Publicado: (2020)

1410. Isoniazid Therapy for Latent Tuberculosis Infection in Patients with Cancer Treated with Checkpoint Inhibitors Immunotherapy
por: Malek, Alexandre, et al.
Publicado: (2021)

Endoscopic vacuum therapy for treatment of spontaneous and iatrogenic upper gastrointestinal defects
por: Panneerselvam, Kavea, et al.
Publicado: (2023)

Concurrent immune checkpoint inhibition and selective immunosuppressive therapy in patients with immune-related enterocolitis
por: Badran, Yousef R, et al.
Publicado: (2023)

Cancer Treatment Response to Checkpoint Inhibitors Is Associated with Cytomegalovirus Infection
por: Villanueva, Faith, et al.
Publicado: (2020)

Role of C-Reactive Protein in Predicting the Severity and Response of Immune-Mediated Diarrhea and Colitis in Patients with Cancer
por: Liu, Cynthia, et al.
Publicado: (2023)

Cytomegalovirus Infections in Patients Treated With Immune Checkpoint Inhibitors for Solid Malignancies
por: Anastasopoulou, Amalia, et al.
Publicado: (2023)

Determination of Catechin and Epicatechin Content in Chocolates by High-Performance Liquid Chromatography
por: Gottumukkala, Raju V. S. S., et al.
Publicado: (2014)

Early introduction of selective immunosuppressive therapy associated with favorable clinical outcomes in patients with immune checkpoint inhibitor–induced colitis
por: Abu-Sbeih, Hamzah, et al.
Publicado: (2019)

Implementing an immunotherapy toxicity (IOTOX) GI service improves outcomes in patients with immune-mediated diarrhea and colitis
por: Saji, Alice, et al.
Publicado: (2022)

Isolated Gastritis Secondary to Immune Checkpoint Inhibitors Complicated by Superimposed Cytomegalovirus Infection
por: Nguyen, Anita H., et al.
Publicado: (2022)

Factors contributing to the risk of cytomegalovirus infection in patients receiving renal transplants.
por: Ho, M., et al.
Publicado: (1976)

Patients with non-colorectal cancers may be at elevated risk of colorectal neoplasia
por: Abu-Sbeih, Hamzah, et al.
Publicado: (2020)

Survival Among Veterans Receiving Steroids for Immune-Related Adverse Events After Immune Checkpoint Inhibitor Therapy
por: Van Buren, Inga, et al.
Publicado: (2023)

Cytomegalovirus pancreatitis in an immunocompetent patient
por: Saeed, Muhammad I., et al.
Publicado: (2020)

Cytomegalovirus Treatment
por: Tan, Ban Hock
Publicado: (2014)

Cytomegalovirus reactivation in esophageal cancer patients receiving chemoradiotherapy: A retrospective analysis
por: Kitagawa, Koichi, et al.
Publicado: (2021)

Influenza vaccination and myocarditis among patients receiving immune checkpoint inhibitors
por: Awadalla, Magid, et al.
Publicado: (2019)

Patients with breast cancer may be at higher risk of colorectal neoplasia
por: Abu-Sbeih, Hamzah, et al.
Publicado: (2019)

Microbiome influencers of checkpoint blockade–associated toxicity
por: Wang, Yinghong, et al.
Publicado: (2023)

A Prospective Study of Cytomegalovirus-Specific Cell-Mediated Immune Monitoring and Cytomegalovirus Infection in Patients With Active Systemic Lupus Erythematosus Receiving Immunosuppressants
por: Bruminhent, Jackrapong, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_h7fs00rsqb93r08olu94uivha8